文献速递乳腺癌

达尔西利联合来曲唑或阿那曲唑对比安慰剂联合来曲唑或阿那曲唑一线治疗激素受体阳性、HER2阴性晚期乳腺癌患者(DAWNA-2):多中心、随机、双盲、安慰剂对照3期试验

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2023-05-11

DAWNA-2研究在中国42家医院纳入456例既往未接受过晚期系统治疗的激素受体阳性、HER2阴性晚期乳腺癌患者,按2:1随机接受达尔西利或安慰剂联合来曲唑或阿那曲唑。达尔西利组中位无进展生存期显著延长(30.6个月 vs 18.2个月;分层HR 0.51,95%CI 0.38-0.69;单侧P<0.0001)。3或4级不良事件发生率达尔西利组90%,安慰剂组12%。

要点

  • 达尔西利组中位PFS 30.6个月,安慰剂组18.2个月,分层HR 0.51(95%CI 0.38-0.69)。
  • 达尔西利组3或4级中性粒细胞减少259例(86%),安慰剂组无。
  • 达尔西利组发生2例治疗相关死亡(原因不明),安慰剂组无。

核心结论

  • 达尔西利联合来曲唑或阿那曲唑可能成为激素受体阳性、HER2阴性晚期乳腺癌患者的新一线标准治疗,并可作为当前治疗格局的替代选择。

研究设计与样本

  • DAWNA-2为在中国42家医院开展的多中心、随机、双盲、安慰剂对照3期试验。
  • 2019年7月19日至2020年12月25日筛查580例,456例合格并随机分配至达尔西利组(n=303)或安慰剂组(n=153)。
  • 随机按2:1进行,使用交互式网络应答系统(区组大小6),按内脏转移、辅助或新辅助内分泌治疗史、内分泌治疗搭档分层。
  • 主要终点为研究者评估的无进展生存期,在符合入选标准的意向性治疗人群中分析;安全性在至少接受一剂研究治疗的全部随机患者中分析。

主要发现

  • 数据截止2022年6月1日,中位随访21.6个月(IQR 18.3-25.9)。
  • 达尔西利组303例中103例(34%)发生疾病进展或死亡,安慰剂组153例中83例(54%)发生疾病进展或死亡。
  • 达尔西利组中位无进展生存期30.6个月(95%CI 30.6-未达到),安慰剂组18.2个月(95%CI 16.5-22.5);分层风险比0.51(95%CI 0.38-0.69);单侧log-rank P<0.0001。
  • 达尔西利组302例中271例(90%)报告3或4级不良事件,安慰剂组153例中18例(12%)报告。
  • 最常见的3或4级不良事件为中性粒细胞减少(达尔西利组259例[86%] vs 安慰剂组无)和白细胞减少(达尔西利组201例[67%] vs 安慰剂组无)。

关键数值与推荐

  • 优效性界值为单侧P≤0.0076。
  • 达尔西利给药方案:口服150 mg每日一次,连续3周后停药1周。
  • 内分泌治疗搭档:来曲唑2.5 mg或阿那曲唑1 mg口服每日一次持续给药。

临床怎么用

  • 作者认为达尔西利联合来曲唑或阿那曲唑可能成为激素受体阳性、HER2阴性晚期乳腺癌的新一线标准治疗,并可作为当前治疗格局的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adding CDK4/6 inhibitor dalpiciclib to fulvestrant significantly prolonged progression-free survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer progressing after endocrine therapy. We aimed to assess the efficacy and safety of dalpiciclib plus letrozole or anastrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer who had no previous systemic therapy in the advanced setting. METHODS: DAWNA-2 is a randomised, double-blind, placebo-controlled, phase 3 trial done at 42 hospitals in China. Eligible patients were aged 18-75 years, of any menopausal status, had an ECOG performance status of 0-1, and had pathologically confirmed hormone receptor-positive, HER2-negative untreated advanced breast cancer. Patients were randomly assigned (2:1) to receive oral dalpiciclib (150 mg per day for 3 weeks, followed by 1 week off) or matching placebo. Both groups also received endocrine therapy: either 2·5 mg letrozole or 1 mg anastrozole orally once daily continuously. Randomisation was using an interactive web response system (block size of six) and stratified according to visceral metastasis, previous endocrine therapy in the adjuvant or neoadjuvant setting, and endocrine therapy partner. All investigators, patients, and the funders of the study were masked to group allocation. We present the results of the preplanned interim analyses for the primary endpoint of investigator-assessed progression-free survival, which was assessed in all randomly assigned patients who met the eligibility criteria by intention-to treat. Safety was analysed in all randomly assigned patients who received at least one dose of study treatment. The superiority boundary was calculated as a one-sided p value of 0·0076 or less. This trial is registered with ClinicalTrials.gov, NCT03966898, and is ongoing but closed to recruitment. FINDINGS: Between July 19, 2019, and Dec 25, 2020, 580 patients were screened and 456 were eligible and randomly assigned to the dalpiciclib group (n=303) or placebo group (n=153). At data cutoff (June 1, 2022), median follow-up was 21·6 months (IQR 18·3-25·9), and 103 (34%) of 303 patients in the dalpiciclib group and 83 (54%) of 153 patients in the placebo group had disease progression or died. Median progression-free survival was significantly longer in the dalpiciclib group than in the placebo group (30·6 months [95% CI 30·6-not reached] vs 18·2 months [16·5-22·5]; stratified hazard ratio 0·51 [95% CI 0·38-0·69]; one-sided log-rank p<0·0001). Adverse events of grade 3 or 4 were reported in 271 (90%) of 302 patients in the dalpiciclib group and 18 (12%) of 153 patients in the placebo group. The most common adverse events of grade 3 or 4 were neutropenia (259 [86%] in the dalpiciclib group vs none in the placebo group) and leukopenia (201 [67%] vs none). Serious adverse events were reported for 36 (12%) patients in the dalpiciclib group and ten (7%) patients in the placebo group. Two treatment-related deaths occurred, both in the dalpiciclib group (deaths from unknown causes). INTERPRETATION: Our findings suggest that dalpiciclib plus letrozole or anastrozole could be a novel standard first-line treatment for patients with hormone receptor-positive, HER2-negative advanced breast cancer, and is an alternative option to the current treatment landscape. FUNDING: Jiangsu Hengrui Pharmaceuticals and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang P, Zhang Q, Tong Z, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023. PMID: 37182538. doi:10.1016/S1470-2045(23)00172-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。